



February 4, 2025

Company name: SanBio Co., Ltd.

Representative: Keita Mori, Representative Director
and President
(TSE Growth Code: 4592)

Contact: Yoshihiro Kakutani, Corporate Officer
of Management Administration
(TEL. +81-3-6264-3481)

Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 2025

SanBio Co., Ltd. (hereafter, the “Company”) hereby announces that it has revised its consolidated earnings forecast for the fiscal year ending January 2025 (February 1, 2024–January 31, 2025) announced on March 18, 2024 as below.

1. Revision of consolidated earnings forecast for the fiscal year ending January 2025 (February 1, 2024–January 31, 2025)

	(Million yen)				
	Operating revenue	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share (yen)
Previous forecast (A) (Announced March 18, 2024)	-	(3,339)	(3,359)	(3,359)	(49.45)
Revised forecast (B)	-	(3,339)	(2,736)	(2,736)	(38.57)
Change (B) – (A)	-	-	623	623	
Rate of change (%)	-	-	-	-	
(Ref.) FY2024.1 results	-	(4,539)	(2,824)	(2,644)	(40.48)

2. Reasons for change

The company revised its original full-year earnings forecast, due to the estimated amount of foreign exchange gains related to foreign currency denominated loans and related receivables from our consolidated subsidiaries to be approximately 623 million yen, as the exchange rates at the end of the fiscal year have been determined.

Due to the generated foreign exchange gains from intergroup transactions, the company will record the foreign exchange account adjustment account in comprehensive income (a negative adjustment in comprehensive income).

Note: Earnings estimates provided above were calculated based on information available to the Company at the time of the disclosure of this document, and may differ from actual results due to various factors.